ImetelChat

Rise like the Pheonix tomorrow Gern!!!

2018 was likely a pump and dump by those with inside information. As many here have noted, the stock was being heavily shorted even though most, if not all, of the tea leaves indicated that J&J was going to continue with Imetelstat. Seeking Alpha published new positive articles literally every week....

Thanks to all for the tremendous (though slightly edgy), Holiday/TLR posts. If you're feeling a bit 'edgy' - take a look at the 5-day chart for Madrigal Pharmaceuticals after they posted Phase III Resmetirom results on Monday. Enjoy and Happy Holidays!!! https://finance.yahoo.com/quote/MDGL?p=MDGL&....

Great post Ryan - well said, thanks!!!

Thanks, BP, your insights are greatly appreciated!!!

Ditto, MG

Bridge - Geron is up 64% YTD - no tax loss selling for Geron.

Extremely encouraging news Kamal - mucho gracias for sharing your research!!!

BP, At approximately the 8:30 mark of today's presentation, Dr. Feller referred to the potential for Disease Modifying data to be included in a subsequent publication to the TLR in early January. She stated repeatedly that the Phase II results seem to confirm DMOA. Dr. Feller sounded very confident.

Hi Signit,

Yahoo recently changed the format and I seemed to have trouble initially seeing all of the messages but I can see them now. Did you sign in - not sure if it's required now?

Thanks, BP & Ryan - hopefully Scarlett will address this at the 11/3 press conference.

https://news.bms.com/news/details/2022/ ... fault.aspx

Hi BP,

Can you comment on the results reported in this study - thanks!

Great find Bridge. Agree BP - she was literally born for the job, extremely intelligent, articulate, and passionately focused on inhibitors for blood cancers. After listening to this interview I have to believe that she has a great deal of confidence in Imetelstat's efficacy otherwise she would be s...

Imetelstat and HIF inhibitors evolving use in MDS
Valeria Santini University of Florence, Florence, Italy

https://www.vjhemonc.com/event/iwmds-2022/

At Minute 8:08 Dr Santini states that she's had patients on Imetelstat for years - very positive video.

SETTLEMENT DATE SHORT INTEREST AVG. DAILY SHARE VOLUME DAYS TO COVER 07/15/2022 16,512,514 3,021,505 5.464996 06/30/2022 24,665,218 4,155,179 5.936018 06/15/2022 26,700,061 1,968,287 13.565126 !0 million shares covered in 30 days (21 trading days) approximately 500K per day. As a frame of reference ...

BP - Thx for posting our Required Reading. My layman's understanding is that MMB (similar to RUX in that both are JAK Inhibitors) was more effective in TI (Transfusion Independence) than RUX and that anemia is a significant indicator of disease progression for MF. This study seemed to indicate that ...

Thanks BP, from the study: "Collectively, these data indicate that alterations of scheduling of the administration of Rux and Ime affect the efficacy of this drug combination in depleting MF HPC/HSCs. We propose that cycles of Rux followed by Ime represent a potentially effective therapeutic strateg...

LWS, I understand that the trial is underway. My question is; What do knowledgeable folks think the combo would have on the lifespan of MF patients and how significantly would this combo impact potential revenue?

If Imetelstat extends the life of refractory Jakafi patients for over 30 months, and if a combination Jakafi/Imetelstat MF trial proves to be safe and effective, what would be the impact on the lifespan of the patient be if the Imet treatment started much earlier in the progression of the disease? F...

Hat tip to you BP. Great find. Things are looking up. I wonder if Bridge sees these hires for potential EAP duties as a positive Hope so, I know I do.